Basic Information
Lutetium (177Lu) chloride Billev (previously Illuzyce)
Regulatory Information
EMEA/H/C/005859
September 15, 2022
July 21, 2022
3
November 29, 2024
Company Information
Denmark
Slotsmarken 10 2970 Hoersholm
BILLEV PHARMA ApS
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.
Overview Summary
Lutetium (177Lu) chloride Billev is a solution containing a radioactive form of lutetium (177lu) that is used for radiolabelling other medicines. Radiolabelling is a technique where a substance is labelled with a radioactive compound. Once the substance is radiolabelled with Lutetium (177Lu) chloride Billev, it then carries the radioactivity to where it is needed in the body (for example, the site of a tumour). Lutetium (177Lu) chloride Billev is used to radiolabel medicines that have been specifically developed for use with lutetium (177lu) chloride. Lutetium (177Lu) chloride Billev contains the active substance lutetium (177lu) chloride.